Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

Michael B. Atkins, MD
Published: Wednesday, Aug 02, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

According to Atkins, an issue that physicians are facing is whether to give first-line and second-line treatments together versus giving them in sequence.

The immunotherapies are all being tested in the adjuvant setting with data to be released in the coming years. This will further complicate the sequencing of agents for patients with RCC, states Atkins.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

According to Atkins, an issue that physicians are facing is whether to give first-line and second-line treatments together versus giving them in sequence.

The immunotherapies are all being tested in the adjuvant setting with data to be released in the coming years. This will further complicate the sequencing of agents for patients with RCC, states Atkins.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x